Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Small molecules in anti-angiogenic therapy.

Raffaella Giavazzi1, Maria Ines Nicoletti

  • 1Department of Oncology, Mario Negri Institute for Pharmacological Research, Bergamo, Italy. giavazzi@marionegri.it

Current Opinion in Investigational Drugs (London, England : 2000)
|June 11, 2002
PubMed
Summary

Targeting angiogenesis, the formation of new blood vessels, offers a novel cancer therapy. This review examines anti-angiogenic compounds and their clinical trial development for cancer treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impairment of oxidative metabolism compromises Rad51 recruitment and potentiates PARP inhibitor effectiveness in ovarian cancer.

Journal of experimental & clinical cancer research : CR·2026
Same author

Stroma gene signature predicts responsiveness to chemotherapy in pancreatic ductal adenocarcinoma patient-derived xenograft models.

Molecular oncology·2025
Same author

Melanoma extracellular vesicles membrane coated nanoparticles as targeted delivery carriers for tumor and lungs.

Materials today. Bio·2025
Same author

BRCA1 foci test as a predictive biomarker of olaparib response in ovarian cancer patient-derived xenograft models.

Frontiers in pharmacology·2024
Same author

Tumor microenvironment-induced FOXM1 regulates ovarian cancer stemness.

Cell death & disease·2024
Same author

Editor's Note: Antiangiogenic Properties of 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin: An Orally Bioavailable Heat Shock Protein 90 Modulator.

Clinical cancer research : an official journal of the American Association for Cancer Research·2024

Area of Science:

  • Oncology
  • Vascular Biology

Background:

  • Angiogenesis is crucial for physiological and pathological processes, notably cancer growth.
  • The discovery of pro-angiogenic factors and endogenous inhibitors has spurred therapeutic strategies targeting vessel formation.
  • Anti-angiogenic and antivascular compounds show promise in preclinical cancer studies.

Purpose of the Study:

  • To review classes of molecules that specifically target the angiogenic process.
  • To discuss the developmental stage and clinical trial characteristics of these anti-angiogenic compounds.

Main Methods:

  • Literature review of compounds interfering with angiogenesis.
  • Analysis of preclinical data and clinical trial information for anti-angiogenic agents.

Main Results:

  • Several classes of molecules targeting angiogenesis have been identified.
  • Some compounds have progressed to patient studies in cancer, demonstrating preclinical efficacy.
  • Challenges exist in designing and interpreting clinical trials for non-cytotoxic anti-angiogenic agents.

Conclusions:

  • Interference with angiogenesis is a viable therapeutic strategy for cancer.
  • Further research and optimized trial designs are needed to fully realize the potential of anti-angiogenic therapies.
  • Understanding the specific mechanisms and clinical performance of these agents is critical for advancing cancer treatment.

Related Experiment Videos